VYGR
Voyager Therapeutics Inc
NASDAQ: VYGR · HEALTHCARE · BIOTECHNOLOGY
$3.73
+2.47% today
Updated 2026-04-30
Market cap
$224.69M
P/E ratio
—
P/S ratio
5.57x
EPS (TTM)
$-2.04
Dividend yield
—
52W range
$3 – $6
Volume
0.7M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+5.0
Quality
C+2.0
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$14.89
+299.20%
12-Month target
—
—
Intrinsic (DCF)
$14.61
Margin of safety
+76.59%
0 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 144.30% QoQ
+ 76.59% below intrinsic value
Risks
- Thin margins at -296.50%
- Negative free cash flow $-30.89M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $40.91M | $250.01M | $80.00M | $40.37M | $40.37M |
| Net income | $-46.41M | $132.33M | $-65.00M | $-119.72M | $-27.43M |
| EPS | — | — | — | — | $-2.04 |
| Free cash flow | $-15.00M | $74.66M | $-18.83M | $-135.06M | $-30.89M |
| Profit margin | -113.45% | 52.93% | -81.25% | -296.53% | -296.50% |
Peer comparison
Smart narrative
Voyager Therapeutics Inc trades at $3.73. Our Smart Value Score of 35/100 indicates the stock is weak. TTM revenue stands at $40.37M. with profit margins at -296.50%. Our DCF model estimates intrinsic value at $14.61.
Frequently asked questions
What is Voyager Therapeutics Inc's stock price?
Voyager Therapeutics Inc (VYGR) trades at $3.73.
Is Voyager Therapeutics Inc overvalued?
Smart Value Score 35/100 (Grade D, Sell). DCF value $14.61.
What is the price target of Voyager Therapeutics Inc (VYGR)?
The analyst target price is $14.89, representing +299.2% upside from the current price of $3.73.
What is the intrinsic value of Voyager Therapeutics Inc (VYGR)?
Based on our DCF model, intrinsic value is $14.61, a +76.6% margin of safety versus $3.73.
What is Voyager Therapeutics Inc's revenue?
TTM revenue is $40.37M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.57x
ROE-48.30%
Beta1.38
50D MA$3.99
200D MA$4.02
Shares out0.06B
Float0.04B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—